Physician profile
Erik Domingues
NPI 1962713370
$735,849.54
in general payments reported to CMS, 2019-2025
29 companies · $359K in 2025
The $359K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,927 · 2020: $299 · 2021: $1,327 · 2022: $2,072 · 2023: $96K · 2024: $275K · 2025: $359K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $368K · Consulting Fee: $275K · Travel and Lodging: $57K · Food and Beverage: $29K · Honoraria: $260 · Education: $213 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $43.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $368,383.83 |
| Consulting Fee | $275,393.75 |
| Travel and Lodging | $57,339.91 |
| Food and Beverage | $28,589.69 |
| Honoraria | $260.08 |
| Education | $213.13 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $43.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $223,339.46 | 2023-2025 | Zoryve |
| Pfizer INC. | $167,885.93 | 2019-2025 | |
| Incyte Corporation | $158,301.15 | 2022-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $65,374.38 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $56,297.81 | 2019-2025 | Nemluvio, Dysport, Aklief |
| Ucb, INC. | $44,083.42 | 2019-2025 | Bimzelx |
| Abbvie INC. | $12,380.61 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $3,903.72 | 2019-2025 | Tremfya, Simponi, Stelara |
| Leo Pharma INC. | $996.12 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Kowa Pharmaceuticals America, INC. | $650.00 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $408.23 | 2019-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $392.61 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $307.71 | 2019-2024 | Dupixent |
| Genzyme Corporation | $249.75 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $227.41 | 2019-2025 | Jublia, Siliq, Cabtreo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $226.12 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Eli Lilly and Company | $175.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Allergan, INC. | $97.33 | 2019 | |
| Amgen INC. | $89.04 | 2020-2022 | |
| Revance Therapeutics, INC. | $61.92 | 2024 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.88 | 2022-2023 | Spevigo |
| Stemline Therapeutics INC. | $57.11 | 2021 | |
| Blueprint Medicines Corporation | $48.03 | 2025 | Ayvakit |
| Lnhc, INC | $39.52 | 2025 | Zelsuvmi |
| Medline Industries Lp | $29.20 | 2024 | |
| Celgene Corporation | $20.50 | 2019 | |
| Merz North America, INC. | $15.97 | 2020 | |
| Organon LLC | $5.61 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Domingues listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.